Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Median OS Not Yet Reached In PD-L1-Positive Patients
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.
You may also be interested in...
Merck KGaA’s short-course oral MS therapy Mavenclad may gain a boost from new data suggesting its use does not affect the beneficial response of patients to COVID-19 vaccines, as the research and manufacturing reagents and solutions business unit of the diversified big pharma reported a strong first quarter due to pandemic-related demand.
The German drugmaker is seeing growing demand for its services from peers in the pharma world that are looking to develop vaccines to tackle the COVID-19 pandemic.
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.